Isaac E. Ciechanover, Chief Executive Officer at Atara Biotherapeutics, Inc. (ATRA), sold 7,800 shares at $34.98 ($273K) on 2019-01-24, disclosed to the SEC on 2019-01-25.
Scheduled sale ($273k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $34.84 | 3,000 | $105K | 38.2% |
| 2 | $35.59 | 800 | $28K | 10.4% |
| 3 | $36.58 | 100 | $4K | 1.3% |
| 4 | $34.98 | 3,470 | $121K | 44.4% |
| 5 | $35.82 | 430 | $15K | 5.6% |
| Total | $35.06 avg | 7,800 |
| $273K |
| 100% |
| Filing → |
| ATRA | SELL | 2019-04-29 | $262K | — | Filing → |
| ATRA | SELL | 2019-04-12 | $286K | — | Filing → |
| ATRA | SELL | 2019-04-01 | $81K | — | Filing → |